Matrix metalloproteinase-2 promoter genotype as a marker of cutaneous T-cell lymphoma early stage
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články
PubMed
20625418
PubMed Central
PMC2896886
DOI
10.1155/2010/805907
Knihovny.cz E-zdroje
- MeSH
- dospělí MeSH
- genetická predispozice k nemoci MeSH
- kožní T-buněčný lymfom enzymologie genetika patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- matrixová metaloproteinasa 2 genetika MeSH
- nádorové biomarkery genetika MeSH
- nádory kůže enzymologie genetika patologie MeSH
- parapsoriáza genetika MeSH
- promotorové oblasti (genetika) * MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- staging nádorů MeSH
- studie případů a kontrol MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- matrixová metaloproteinasa 2 MeSH
- nádorové biomarkery MeSH
The aim of the study was to investigate the DNA polymorphic genotype in MMP-2 promoter gene as a potential candidate region for the development of the cutaneous T-cell lymphoma (CTCL) and/or its progression. A total of 89 Czech patients with CTCL (including 23 patients with large plaque parapsoriasis) were compared to 198 controls of similar age and sex distribution, without personal or family history of chronic skin diseases and without personal history of malignancy. The three selected polymorphisms in the promoter of MMP-2 gene (-1575G/A, -1306C/T, and -790T/G) were determined using the PCR-based methodology with RFLP. In our cohort, the associated GGCCTT MMP-2 promoter genotype was highly significantly more frequent in CTCL-Ia stage patients compared to patients with parapsoriasis, the tests having high sensitivity and specificity (78%, 83%, resp.). To conclude, use of associated MMP-2 promoter genotype as a DNA marker might make it possible to distinguish between the patients with parapsoriasis and those with CTCL stage Ia, which could substantially improve possibilities of clinical diagnostics, therapy design, and prognosis of this serious condition in the early stages.
Zobrazit více v PubMed
Hauzenberger D, Bergström SE, Klominek J, Sundqvist KG. Spectrum of extracellular matrix degrading enzymes in normal and malignant T lymphocytes. Anticancer Research. 1999;19(3):1945–1952. PubMed
Nabeshima K, Suzumiya J, Nagano M, et al. Emmprin, a cell surface inducer of matrix metalloproteinases (MMPs), is expressed in T-cell lymphomas. Journal of Pathology. 2004;202(3):341–351. PubMed
Vacca A, Moretti S, Ribatti D, et al. Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9. European Journal of Cancer. 1997;33(10):1685–1692. PubMed
Vacca A, Ribatti D, Ria R, et al. Proteolytic activity of human lymphoid tumor cells. Correlation with tumor progression. Developmental Immunology. 2000;7(2–4):77–88. PubMed PMC
Hahtola S, Tuomela S, Elo L, et al. Th1 response and cytotoxicity genes are down-regulated in cutaneous T-cell lymphoma. Clinical Cancer Research. 2006;12(16):4812–4821. PubMed
Arlt M, Kopitz C, Pennington C, et al. Increase in gelatinase-specificity of matrix metalloproteinase inhibitors correlates with antimetastatic efficacy in a T-cell lymphoma model. Cancer Research. 2002;62(19):5543–5550. PubMed
Krüger A, Arlt MJE, Gerg M, et al. Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Research. 2005;65(9):3523–3526. PubMed
Kashani-Sabet M, McMillan A, Zackheim HS. A modified staging classification for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology. 2001;45(5):700–706. PubMed
Vašků A, Goldbergová M, Hollá LI, et al. A haplotype constituted of four MMP-2 promoter polymorphisms (-1575G/A, -1306C/T, -790T/G and -735C/T) is associated with coronary triple-vessel disease. Matrix Biology. 2004;22(7):585–591. PubMed
Sarveswari KN, Yesudian P. The conundrum of parapsoriasis versus patch stage of mycosis fungoides. Indian Journal of Dermatology, Venereology and Leprology. 2009;75(3):229–235. PubMed
Santucci M, Biggeri A, Feller AC, Massi D, Burg G. Efficacy of histologic criteria for diagnosing early mycosis fungoides: an EORTC cutaneous lymphoma study group investigation. American Journal of Surgical Pathology. 2000;24(1):40–50. PubMed
Bernier C, Nguyen J-M, Quéreux G, Renault J-J, Bureau B, Dreno B. CD13 and TCR clone: markers of early mycosis fungoides. Acta Dermato-Venereologica. 2007;87(2):155–159. PubMed
Harendza S, Lovett DH, Panzer U, Lukacs Z, Kühnl P, Stahl RAK. Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness. The Journal of Biological Chemistry. 2003;278(23):20490–20499. PubMed
Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene. Role of Sp1 in allele-specific transcriptional regulation. The Journal of Biological Chemistry. 2001;276(10):7549–7558. PubMed
Deniaud E, Baguet J, Mathieu A-L, Pagès G, Marvel J, Leverrier Y. Overexpression of Sp1 transcription factor induces apoptosis. Oncogene. 2006;25(53):7096–7105. PubMed
Segre JA, Bauer C, Fuchs E. Klf4 is a transcription factor required for establishing the barrier function of the skin. Nature Genetics. 1999;22(4):356–360. PubMed
Evans PM, Chen X, Zhang W, Liu C. KLF4 interacts with β-catenin/TCF4 and blocks p300/CBP recruitment by 㬡-catenin. Molecular and Cellular Biology. 2010;30(2):372–381. PubMed PMC
Wu B, Crampton SP, Hughes CCW. Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. Immunity. 2007;26(2):227–239. PubMed PMC
Fuchs O. EVI1 and its role in myelodysplastic syndrome, myeloid leukemia and other malignant diseases. Casopis Lekaru Ceskych. 2006;145(8):619–624. PubMed
